SLDB Q1 2024 Earnings — Solid Biosciences Inc. Revenue & Financial Results | Market Cap Arena

SLDBSolid Biosciences Inc.

$644M

Q1 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$327,000

Operating Income

-$27M

Net Income

-$24M

EPS (Diluted)

$-0.64

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$25M

Free Cash Flow

-$25M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$249M

Total Liabilities

$38M

Stockholders' Equity

$211M

Cash & Equivalents

$118M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$327,000	$0	—
Operating Income	-$27M	-$32M	+16.1%
Net Income	-$24M	-$30M	+19.2%